Biomarker Verification in Pediatric Chronic Graft-Versus-Host Disease: Applied Biomarkers to Minimize Long Term Effects of Childhood/Adolescent Cancer Treatment (ABLE)
Primary Objective
PRIMARY OBJECTIVE Validate and implement a risk-assignment biomarker algorithm at day +100 (+/- 14 days) that predicts the future risk of chronic (cGvHD) and late-acute GvHD (L-aGvHD), and based upon these results, group study participants into “risk groups” that predict a future high-risk (>45%), intermediate-risk (10-45%), or low risk (<10%) for the development of L-aGvHD and cGvHD. SECONDARY OBJECTIVES 1. Determine the possibility of a biomarker risk-assignment at day +60 (+/- 7 days) that will identify study participants at risk for developing cGvHD early post-transplant (between days 70 –114) and include them in the biomarker algorithm. 2. Investigate the opinions of selected clinicians on feasibility or necessity of patient’s Biomarker Risk Assignment concept. 3. Develop the Biomarker Signature Panels (BSPs) at the onset of both late acute and chronic GvHD, based on differences in biomarker expression profile.
Description
The Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) study, in collaboration with the Pediatric Transplantation & Cellular Therapy Consortium (PTCTC), have recently focused on biological correlates (such as T- and B-cells and their respective subsets, NK cells and their subsets, regulatory cell populations, and plasma proteins including cytokines and chemokines) that can be easily measured (using a blood sample) before the onset of cGvHD as a way to predict which patients are at a higher- or lower-risk for the future development of cGvHD. In doing so, our goal is to develop a clinically applicable biomarker algorithm, whereby patients with a lower risk for developing cGvHD (<10% risk) might have their prophylactic immune suppression withdrawn earlier (and hence avoid additional toxicity and cost, while enhancing immune reconstitution after transplant), while those at higher risk for later developing cGvHD (approximately 45% risk or higher) could potentially be enrolled on early phase clinical trials testing pre-emptive immune suppressive therapies, aimed at reducing the future risk of developing this severe complication.
Details
Locations
Childrens Hospital Colorado
Principal Investigator
Laura McLaughlin
Study ID
Protocol Number: 21-3395
More information available at ClinicalTrials.gov: NCT04372524
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers